Exhibit 99.1 Contact: Trinity Biotech plc LifeSci Partners, LLC Des Fitzgerald Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance -Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and sca ...